It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
Expert Panel Broadly OKs Draft Report on Pharma Policies, Further Deliberations by Other Forums
To read the full story
Related Article
- Expert Panel Report Failed to Delve into Annual Price Cuts, Irking Pharma Officials
June 30, 2023
- MHLW Publishes Final Report by Expert Panel on Comprehensive Pharma Policy
June 13, 2023
- Pharma Hails Expert Panel Report, Looks for Govt Leadership to Execute Reforms
June 7, 2023
- Expert Panel to Propose Setting Up Requirements for Generic Entry to Ensure Stable Supplies; Draft Report Due Out June 6
June 5, 2023
- Expert Panel Wants to See Action on Excessive Yakkasa, No Direction on Buffer Zone: Draft Report
June 5, 2023
- Expert Panel Pushes Fresh Evaluation Approach for New Drug Pricing, Rethink of Spillovers: Draft Report
June 5, 2023
REGULATORY
- Komeito’s Yoko Wanibuchi Newly Named Senior Vice Health Minister
October 4, 2024
- Panel OKs Withdrawal Rule for Conditional Nod, 2-Year Extension for Pediatric Data Protection towards PMD Act Amendment
October 4, 2024
- New Health Minister Eager to Build Pharma Ecosystem in Japan
October 3, 2024
- AMED to Assign Staff by Seed to Ensure End-to-End Support from FY2025
October 3, 2024
- New Finance Minister Vows Full Discussions with MHLW on FY2025 Revision
October 3, 2024
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…